Comparing the Effects of Smart App-Assited Super-Slow Jogging and Stationary Cycling on Respiratory Function and Aerobic Fitness in College Students

As health awareness continues to rise, more people are prioritizing exercise to improve physical condition and enhance overall fitness. For those lacking exercise habits, selecting a simple, accessible, and effective workout becomes crucial. Against a backdrop of prolonged sitting and inactivity, "super slow jogging" is gaining attention. This aerobic exercise involves a slow walking pace and low intensity, yet burns more calories than regular walking, making it an ideal entry-level activity for beginners or those with lower fitness levels. This study aims to investigate whether incorporating super slow jogging training can effectively enhance cardiorespiratory fitness and respiratory function, comparing its outcomes with other exercise types. The purpose of this experiment is academic research, primarily exploring the impact of exercise intervention on physiological functions. It is not intended for health screening or medical diagnosis.

Study Overview

• Status: Recruiting
• Conditions: Young Adult; Sedentary Lifestlye
• Intervention / Treatment: Behavioral: Super slow jogging; Behavioral: moderate exercise training; Behavioral: Control

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Tzu-Pin Weng; Phone Number: +886-7-7811151-7044; Email: ft072@fy.edu.tw

Study Locations

• Taiwan
  • Daliao
    • Kaohsiung City, Daliao, Taiwan, 831301
      • Recruiting
      • No. 151, Jinxue Rd.
      • Contact: Tzu-Pin Weng; Phone Number: +886-7-7811151-7044; Email: ft072@fy.edu.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• required no regular exercise training in the past six months
• ability to safely perform high-intensity cycling exercise

Exclusion Criteria:

• musculoskeletal limitations that prevented cycling exercise
• recent infection
• known cardiopulmonary disease or medical history affecting cardiovascular or respiratory function
• smoking
• use of medications that may influence cardiopulmonary responses to exercise
• other contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Super slow jogging; A smart app will provide pacing assistance, adjusting step frequency weekly: Week 1: 150 steps per minute Week 2: 180 steps per minute Week 3: 190 steps per minute Week 4: 200 steps per minute	Behavioral: Super slow jogging; This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention.
Experimental: moderate exercise training; Continuous cycling training at moderate intensity of 60% VO₂max	Behavioral: moderate exercise training; This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention.
Placebo Comparator: Control; not perform any exercise training	Behavioral: Control; This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cardiopulmonary Fitness	VO2max (ml/kg/mL)	Before intervention and the end of intervention at 12 weeks
Baseline anthropometric of the participants	Age (yr)	Before intervention and the end of intervention at 12 weeks
Cardiopulmonary Fitness	VEmax (L/min)	Before intervention and the end of intervention at 12 weeks
Cardiopulmonary Fitness	AT% (%VO₂max)	Before intervention and the end of intervention at 12 weeks
Cardiopulmonary Fitness	Resting O₂ pulse (mL·beat-¹)	Before intervention and the end of intervention at 12 weeks
Cardiopulmonary Fitness	Max O₂ pulse (mL·beat-¹)	Before intervention and the end of intervention at 12 weeks
Cardiopulmonary Fitness	MIP (cmH2O)	Before intervention and the end of intervention at 12 weeks
Cardiopulmonary Fitness	MEP (cmH2O)	Before intervention and the end of intervention at 12 weeks
Baseline anthropometric of the participants	Height (cm)	Before intervention and the end of intervention at 12 weeks
Baseline anthropometric of the participants	Weight (kg)	Before intervention and the end of intervention at 12 weeks
Baseline anthropometric of the participants	BMI (kg/m²)	Before intervention and the end of intervention at 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lung function	FEV1 (L)	Before intervention and the end of intervention at 12 weeks
Lung function	FVC (L)	Before intervention and the end of intervention at 12 weeks
Lung function	FEV₁/FVC (%)	Before intervention and the end of intervention at 12 weeks
Lung function	FEF25-75% (L·s-¹)	Before intervention and the end of intervention at 12 weeks
Lung function	PEF (L·min-¹)	Before intervention and the end of intervention at 12 weeks
Lung function	MVV (L·min-¹)	Before intervention and the end of intervention at 12 weeks
Lung function	Breathing reserve (%)	Before intervention and the end of intervention at 12 weeks
Lung function	Dynamic Index (DI%)	Before intervention and the end of intervention at 12 weeks

Collaborators and Investigators

• Sponsor: Fooyin University

Study record dates

Study Major Dates

• Study Start (Actual): November 20, 2025
• Primary Completion (Estimated): January 31, 2026
• Study Completion (Estimated): February 28, 2026

Study Registration Dates

• First Submitted: November 21, 2025
• First Submitted That Met QC Criteria: December 29, 2025
• First Posted (Actual): December 30, 2025

Study Record Updates

• Last Update Posted (Actual): December 30, 2025
• Last Update Submitted That Met QC Criteria: December 29, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 114-0561; 114-2813-C-242-003-B (Other Grant/Funding Number: National Science and Technology Council, Taiwan)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No